Restricted accessResearch articleFirst published online 2023-03
Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis
Dual-targeting chimeric antigen receptor (CAR)-T cell therapy has been proposed as a potential solution for overcoming antigen escape during anti-CD19 CAR-T treatment. We performed this systematic review and meta-analysis to investigate the efficacy and safety of this novel treatment in patients with B cell non-Hodgkin lymphoma (B-NHL) and B cell acute lymphoblastic leukemia (B-ALL). We systematically searched relevant literature based on databases (PubMed, Web of Science, Embase and Cochrane) and conference abstracts. The primary outcomes measured were the best objective response rate (ORR) or complete response (CR), 12-month overall survival (OS) and progression-free survival (PFS), cytokine release syndrome (CRS), and neurotoxicity. Fifteen registered prospective open-label clinical trials were included. Among the 260 patients with B-NHL, the pooled best ORR and CR were 77% (95% confidence interval [CI]: 0.71–0.82) and 52% (95% CI: 0.40–0.63), respectively, and the pooled 12-month PFS and OS were 54.0% (95% CI: 0.47–0.61) and 66.0% (95% CI: 0.56–0.77), respectively. In the 159 patients with B-ALL, the combined best CR was observed to be 92% (95% CI: 0.82–0.99) and the pooled 12-month PFS and OS were 65.0% (95% CI: 0.51–0.77) and 73.0% (95% CI: 0.56–0.92), respectively. Moreover, in B-NHL patients, grade ≥3 CRS was observed in 14.0% (95% CI: 0.04–0.29) of these patients, and 5.0% (95% CI: 0.02–0.08) showed grade ≥3 neurotoxicity; in the case of B-ALL patients, grade ≥3 CRS and neurotoxicity occurred in 11.0% (95% CI: 0.04–0.19) and 2.0% (95% CI: 0.00–0.06), respectively. This study demonstrates the safety and clinical efficacy of dual-targeting CAR-T cell therapies in B cell malignancies. Further, well-designed randomized controlled trials are required to establish the role of dual-targeting CAR-T cell therapy in patients with B cell malignancies.
Get full access to this article
View all access options for this article.
References
1.
ShahNN, LeeDW, YatesB, et al.Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol, 2021; 39(15):1650–1659; doi: 10.1200/JCO.20.02262
2.
SchusterSJ, TamCS, BorchmannP, et al.Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol, 2021; 22(10):1403–1415; doi: 10.1016/S1470-S2045(21)00375-2
3.
LockeFL, GhobadiA, JacobsonCA, et al.Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1–2 trial. Lancet Oncol, 2019; 20(1):31–42; doi: 10.1016/S1470-2045(18)30864-7
4.
ParkJH, RiviereI, GonenM, et al.Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med, 2018; 378(5):449–459; doi: 10.1056/NEJMoa1709919
JolyFX, McavoyE, SubkeJA. Synergistic interactions between detritivores disappear under reduced rainfall. Ecology, 2021; 102(4):e3299; doi: 10.1002/ecy.3299
7.
PlaksV, RossiJM, ChouJ, et al.CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 2021; 138(12):1081–1085; doi: 10.1182/blood.2021010930
8.
KailayangiriS, AltvaterB, WiebelM, et al.Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers. Cancers (Basel), 2020; 12(5):1075; doi: 10.3390/cancers12051075
9.
GuoZ, TuS, YuS, et al.Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci, 2021; 112(4):1357–1368; doi: 10.1111/cas.14799
10.
ZhangY, LiS, WangY, et al.A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy. Exp Hematol Oncol, 2022; 11(1):15; doi: 10.1186/s40164-022-00270-5
11.
QinH, RamakrishnaS, NguyenS, et al.Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol Ther Oncolytics, 2018; 11:127–137; doi: 10.1016/j.omto.2018.10.006
12.
CordobaS, OnuohaS, ThomasS, et al.CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: A phase 1 trial. Nat Med, 2021; 27(10):1797–1805; doi: 10.1038/s41591-021-01497-1
13.
ShahNN, JohnsonBD, SchneiderD, et al.Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial. Nat Med, 2020; 26(10):1569–1575; doi: 10.1038/s41591-020-1081-3
14.
SpiegelJY, PatelS, MufflyL, et al.CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: A phase 1 trial. Nat Med, 2021; 27(8):1419–1431; doi: 10.1038/s41591-021-01436-0
15.
WangN, HuX, CaoW, et al.Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood, 2020; 135(1):17–27; doi: 10.1182/blood.2019000017
16.
WangY, YangY, HongR, et al.A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J, 2020; 10(10):105; doi: 10.1038/s41408-020-00371-6
17.
ParmarMK, TorriV, StewartL. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 1998; 17(24):2815–2834; doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8
18.
ZhangY, LiJ, LouX, et al.A prospective investigation of bispecific CD19/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Front Oncol, 2021; 11:664421; doi: 10.3389/fonc.2021.664421
19.
DaiH, WuZ, JiaH, et al.Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol, 2020; 13(1):30; doi: 10.1186/s13045-020-00856-8
20.
WeiG, ZhangY, ZhaoH, et al.A safety and efficacy study. Cancer Immunol Res, 2021; 9(9):1061–1070; doi: 10.1158/2326-6066.CIR-20-0675
21.
OsborneW, MarzoliniM, TholouliE, et al. Phase I Alexander Study of AUTO3, the First CD19/CD22 Dual Targeting CAR-T Therapy, with Pembrolizumab in Patients with Relapsed/Refractory (r/r) DLBCL. 2020 ASCO Virtual Scientific Program, Abstract 8001. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15-suppl.8001 [Last accessed: May 9, 2022].
22.
LiuS, DengB, YinZ, et al.Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol, 2021; 96(6):671–679; doi: 10.1002/ajh.26160
23.
HuY, ZhouY, ZhangM, et al.CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res, 2021; 27(10):2764–2772; doi: 10.1158/1078-0432.CCR-20-3863
24.
ZhangY, WangY, LiuY, et al.Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: A single-arm, phase 1–2 trial. Leukemia, 2022; 36(1):189–196; doi: 10.1038/s41375-021-01345-8
25.
SangW, ShiM, YangJ, et al.Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Med, 2020; 9(16):5827–5838; doi: 10.1002/cam4.3259
26.
PanJ, ZuoS, DengB, et al.Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. Blood, 2020; 135(5):387–391; doi: 10.1182/blood.2019003293
27.
ShalabiH, QinH, SuA, et al.CD19/22 CAR T-cells in children and young adults with B-ALL: Phase I results and development of a novel bicistronic CAR. Blood, 2022; 140(5):451–463; doi: 10.1182/blood.2022015795
28.
Kharfan-DabajaMA, YassineF, AlhajMM, et al.Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. Hematol Oncol Stem Cell Ther, 2022; 15(4):168–175; doi: 10.1016/j.hemonc.2021.09.004
29.
GhafouriS, FenertyK, SchillerG, et al.Real-world experience of axicabtagene ciloleucel and tisagenlecleucel for relapsed or refractory aggressive B-cell lymphomas: A single-institution experience. Clin Lymphoma Myeloma Leuk, 2021; 21(12):861–872; doi: 10.1016/j.clml.2021.07.002
30.
YingZ, SongY, ZhuJ.Effectiveness and safety of anti-CD19 chimeric antigen receptor-T cell immunotherapy in patients with relapsed/refractory large B-cell lymphoma: A systematic review and meta-analysis. Front Pharmacol, 2022; 13:834113; doi: 10.3389/fphar.2022.834113
31.
MengJ, WuX, SunZ, et al.Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: A systematic review and meta-analysis. Front Oncol, 2021; 11:698607; doi: 10.3389/fonc.2021.698607
32.
CrumpM, NeelapuSS, FarooqU, et al.Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood, 2017; 130(16):1800–1808; doi: 10.1002/cac2.12126
33.
AnagnostouT, RiazIB, HashmiSK, et al.Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: A systematic review and meta-analysis. Lancet Haematol, 2020; 7(11):e816–e826; doi: 10.1016/S2352-3026(20)30277-5
34.
GroverP, VeilleuxO, TianL, et al.Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. Blood Adv, 2022; 6(5):1608–1618; doi: 10.1182/bloodadvances.2020003482
35.
NeelapuSS, Locke FL, BartlettNL, et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med, 2017; 377(26):2531–2544; doi: 10.1056/NEJMoa1707447
36.
JacobsonCA, HunterB, ArmandP, et al.Axicabtagene ciloleucel in the real world: Outcomes and predictors of response, resistance and toxicity. Blood, 2018; 132:92; doi: 10.1182/blood-2018-99-117199
37.
NeelapuSS, RossiJM, JacobsonCA, et al.CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. Blood, 2019; 134:203; doi: 10.1182/blood-2019-126218
38.
GhorashianS, KramerAM, OnuohaS, et al.Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med, 2019; 25(9):1408–1414; doi: 10.1038/s41591-019-0549-5
39.
SchultzLM, BaggottC, PrabhuS, et al.Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: A pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol, 2022; 40(9):945–955; doi: 10.1200/JCO.20.03585
40.
DavenportAJ, CrossRS, WatsonKA, et al.Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci U S A, 2018; 115(9):E2068–E2076; doi: 10.1073/pnas.1907056116
41.
JeyakumarN, SmithM.Custom CARs: Leveraging the adaptability of allogeneic CAR therapies to address current challenges in relapsed/refractory DLBCL. Front Immunol, 2022; 13:887866; doi: 10.3389/fimmu.2022.887866
42.
LiK, QianS, HuangM, et al.Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy. Am J Transl Res, 2021; 13(1):156–167.
43.
ChenC, LiK, JiangH, et al.Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother, 2017; 66(4):475–489; doi: 10.1007/s00262-016-1949-8
44.
Al-MansourM, Al-FoheidiM, IbrahimE.Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis. Mol Clin Oncol, 2020; 13(4):33; doi: 10.3892/mco.2020.2103
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
